After losing some value lately, a hammer chart pattern has been formed for Amarin (AMRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Here is how Amarin (AMRN) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Amarin Corporation plc (NASDAQ:AMRN ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Aaron D. Berg - CEO, President & Director Mark Marmur - Corporate Participant Peter L.
AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.
MAMA, BSET and AMRN meet breakout criteria with strong earnings growth and prices near 52-week highs.
Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears.
Here is how Amarin (AMRN) and Abbott (ABT) have performed compared to their sector so far this year.
GTX, LPG and AMRN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 27, 2025.
AMRN jumps 27% after inking an exclusive EU licensing deal with Recordati to expand Vazkepa's reach and cut costs.
Amarin (AMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
From a technical perspective, Amarin Corporation PLC (AMRN) is looking like an interesting pick, as it just reached a key level of support. AMRN's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Here is how Amarin (AMRN) and GSK (GSK) have performed compared to their sector so far this year.